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Abstract
Loss of cell cycle control is a hallmark of cancer, and aberrations in
the cyclin-CDK-RB (cyclin-dependent kinase-retinoblastoma
protein) pathway are common in breast cancer. Consequently,
inhibition of this pathway is an attractive therapeutic strategy, but
results from clinical trials of CDK inhibitors in breast cancer have
been disappointing. A recent study now shows that in cell culture a
selective CDK4/6 inhibitor is preferentially effective in estrogen
receptor-positive (ER+) disease and apparently acts synergistically
with tamoxifen or trastuzumab. These exciting new preclinical data
set the scene for a more targeted approach to further clinical
evaluation wherein this class of drugs is targeted to subgroups of
ER+ patients, including those with resistance to endocrine therapy,
alone or in combination with current standard therapies.
Introduction
Almost as soon as it became clear that cyclin activation of
cyclin-dependent kinases (CDKs) is pivotal to the control of
cell cycle progression, investigations began into the likely role
of cyclins and CDKs in cancer, both in the development and
progression of the disease and as therapeutic targets. The
article by Finn and colleagues [1] in the previous issue of
Breast Cancer Research provides the most recent insight
into targeting this basic cell cycle regulatory mechanism in
the context of breast cancer therapy.
Cyclin D1 was the first mammalian G1 cyclin identified and is
now firmly established as a mammary oncogene [2]. Amplifi-
cation at 11q13, the locus of the CCND1 gene encoding
cyclin D1, occurs in 15% to 20% of breast cancers, and
cyclin D1 overexpression is even more common (up to 50%
of breast cancers) [2,3]. Accumulating evidence that inhibit-
ing the activity of CDKs may be an effective therapy in
cancers, including breast cancer, led to the development of
small molecules that specifically target subgroups of CDKs,
including CDK4 and CDK6, the kinases activated by cyclin
D1 [4].
Though well tolerated, CDK inhibitors that have entered
clinical trials have been of limited efficacy except in haemato-
logical malignancies [5]. One reason for this disappointing
outcome is that early CDK inhibitors frequently targeted
CDK2 and many (though not all) cancer cells are refractory to
CDK2 inhibition [6,7]. However, cells that continue to
proliferate despite CDK2 inhibition are arrested by CDK4
inhibition in vitro [6]. Thus, more selective CDK inhibitors, and
identification of cancer subtypes that are likely to be suscep-
tible to CDK inhibition, are needed to clarify the degree to
which CDK inhibition, alone or in combination with other
therapeutic approaches, may be useful clinically. The publica-
tion by Finn and colleagues [1] is pivotal in this context as it
addresses this need by investigating predictors of response
to the CDK4/6-specific inhibitor PD 0332991 in a panel of
41 immortalised breast epithelial and breast cancer cell lines
representative of the major subtypes of breast cancer.
Determinants of response to CDK4/6 inhibition
PD 0332991 is highly selective for inhibition of CDK4 and
CDK6 [8] and is being tested in ongoing clinical trials in
myeloma and breast cancer [5]. It causes a specific cell cycle
arrest in G1 phase and inhibits proliferation in cultured and
xenografted leukaemia, myeloma, breast cancer, colon
cancer, and lung cancer cells [8,9]. This is accompanied by
decreased phosphorylation of the CDK4/6 substrate retino-
blastoma protein (RB), and cell lines lacking RB, and
therefore not dependent on cyclin D1-CDK4/6 for prolifera-
tion, are resistant to PD 0332991 treatment [8,9]. Thus,
CDK4/6 inhibition appears to be the primary mechanism for
PD 0332991 inhibition of proliferation.
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Finn and colleagues [1] compared baseline gene expression
profiles from 21 cell lines highly sensitive to PD 0332991
(half inhibitory concentration [IC50] <150 nM) and 12
resistant cell lines (IC50 >1 μM) and identified 450 differ-
entially expressed genes. Estrogen receptor-positive (ER+)
cell lines, including those with HER2 amplification, were the
most sensitive, and there was significant overlap between the
gene set associated with PD 0332991 sensitivity and that
which distinguishes breast cancer subtypes [1]. However,
the PD 0332991 sensitivity signature also included genes
that are not part of the subtype signature but are components
of the cyclin D1-RB pathway (for example, RB1,  CCND1,
and  CDKN2A, which encodes p16INK4A, an endogenous
inhibitor of CDK4 and CDK6). Interestingly, some cell lines
were insensitive despite the presence of RB and failed to
downregulate RB phosphorylation following PD 0332991
treatment. Comparison of measures of RB pathway activity
(for example, expression of the RB-responsive gene set [10])
with response to PD 0332991 may give some insight into
whether this insensitivity arises through functional inactivation
of RB and consequent loss of dependence on cyclin
D1-CDK4/6.
Although to date CDK inhibitors have not been particularly
effective in the clinic as single agents, combination studies
have yielded more promising results [5]. Consequently, Finn
and colleagues tested whether there was any interaction
between PD 0332991 and therapies commonly used in the
subtypes of breast cancer most sensitive to CDK4/6 inhibi-
tion: tamoxifen and trastuzumab. In both cases, the
combination synergistically inhibited proliferation [1], and so
the results of an ongoing clinical trial of breast cancer treated
with PD 0332991 in combination with letrozole [5], an
aromatase inhibitor that, like tamoxifen, targets the ER
signalling pathway, will be of particular interest. Synergy
between PD 0332991 and tamoxifen was also apparent in a
tamoxifen-insensitive cell line [1], raising the possibility that
CDK4/6 inhibitors like PD 0332991 may be useful in
endocrine-resistant breast cancers, which are not well served
by current targeted therapies [11]. This latter result is
somewhat unexpected given that cyclin D1-CDK4 is a major
target of tamoxifen-mediated growth arrest [12] and that RB
inactivation causes tamoxifen resistance [10]. Thus, the
mechanistic basis for these apparent synergies requires
further detailed investigation.
Conclusions
The study of Finn and colleagues has important implications
for the further clinical evaluation of PD 0332991 and other
specific CDK4/6 inhibitors in breast cancer. First, it identifies
a subgroup of patients most likely to benefit: the ER+ luminal
subtype. This is perhaps counterintuitive in that these are not
the highly proliferative phenotype but are the subgroup
enriched for cyclin D1 overexpression [2,3]. Second, it identi-
fies potential synergy with standard best practice therapies
(that is, tamoxifen and trastuzumab), which raises the
questions of potential interactions with aromatase inhibitors
and the efficacy of CDK4/6 inhibitors in endocrine- and
trastuzumab-resistant ER+ disease. Finally, this study
emphasises the importance of strong preclinical data and the
identification of potential therapeutic response parameters (in
this case, ER, cyclin D1, and a gene expression signature) in
targeting therapeutic trials to the most appropriate patient
subgroups. Further preclinical and clinical data on this class
of agents in breast cancer are awaited with interest.
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